ArticleJournal of thoracic disease2026
Hyperthermic intrathoracic chemotherapy after cytoreductive surgery in malignant pleural mesothelioma: a single-center retrospective cohort study suggesting increased morbidity without survival benefit.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In the multimodal treatment of pleural mesothelioma (PM), hyperthermic intrathoracic chemotherapy (HITOC) has been investigated as an adjunct to cytoreductive surgery (CRS) to potentially improve local tumor control. The study aimed to evaluate the clinical impact of HITOC as an adjunct to CRS, specifically regarding overall survival (OS), postoperative morbidity and mortality, and operative duration. Methods: This retrospective study compared patients who underwent CRS with HITOC to those without HITOC at our institution between 2010 and 2022. Primary endpoints included OS, operative time, and perioperative morbidity and mortality. Categorical variables were compared using the Fisher's exact test. Survival analyses were performed using the Kaplan-Meier method and compared via the log-rank test. Results: A total of 114 patients underwent CRS for PM, including 14 with HITOC and 100 without. The mean age was 66 years, and 12 patients were female. The mean operative time was longer in the HITOC group (488 Conclusions: In this retrospective single-center cohort, adjunctive HITOC was associated with significantly longer operative time, higher postoperative morbidity, and inferior OS compared with cytoreduction alone. Given the small HITOC sample size and potential residual confounding, these findings should be interpreted cautiously but raise concerns regarding the routine use of HITOC outside clinical trials and highlight the need for prospective comparative evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.